News
Public · Published
Chinese drugmaker Ganzhou Hemay delays Hong Kong listing on market conditions
Ganzhou Hemay Pharmaceutical postponed its global offering and planned Hong Kong listing, citing current market conditions. It had aimed to raise about HK$1.04 billion at up to HK$18.9 per share; the company said applicants will receive full refunds without interest and that it remains committed to listing later.
Published:
Updated:
What happened
Ganzhou Hemay Pharmaceutical postponed its global offering and planned Hong Kong listing, citing current market conditions. It had aimed to raise about HK$1.04 billion at up to HK$18.9 per share; the company said applicants will receive full refunds without interest and that it remains committed to listing later.
Confirmed
Global impact / market context
The delay postpones Hemay’s access to public-market funding. The company had expected more than half of its net proceeds to support development and commercialization of Mufemilast, its psoriasis treatment, so the timing of those plans may depend on when the offering can be completed.
Analyst inference
Hong Kong ranked as the world’s top listing venue in 2025, with equity fundraising rising 164% to $103 billion, according to exchange data. Hemay’s postponement shows that strong annual fundraising did not prevent this company from citing current market conditions for delaying its offering.
Confirmed
What to watch
- Watch for Hemay to announce a new offering timetable; the company said it remains committed to completing the offering and Hong Kong listing in due course. Confirmed
- Look for updates on whether Hemay revises its fundraising terms, including the offer price or amount, since the article gives no replacement terms or date. Analyst inference
- Track whether development and commercialization of Mufemilast proceeds as planned, because more than half of the expected net proceeds had been earmarked for that work. Analyst inference
Evidence
- Original source link unavailable